BOB Capital Markets cuts Abbott India PT on slower sales growth outlook

Abbott India

04/09/2026 10:44

** BOB Capital Markets reiterates "buy" on drugmaker Abbott India ABOT.NS, cuts PT to 30,839 rupees from 37,431 rupees
** Says co's sales growth has slowed after a 35% drop in sales from its licensed Novo portfolio
** Adds Abbott's core portfolio gastro-therapy key brands like Udiliv and Diegene are growing below the market growth rate, hampering overall growth
** Expects co's sales growth to likely to normalize to 8%-9% from prior double-digit levels, translating into low-teens net profit growth
** Brokerage cuts valuation multiple to 32x from 40x
** Stock rated "buy" on average by 7 analysts; median PT at 32,550 rupees - LSEG-compiled data
** Stock down 9.7% YTD


 (Reporting by Payel Das in Bengaluru)
 ((Payel.das@thomsonreuters.com))